|
|
Volumn 18, Issue 3, 2012, Pages 379-380
|
|
Length of adjuvant imatinib therapy in GIST: Weighing benefits, side effects and costs
|
|
Author keywords
adjuvant therapy; cost; GIST; Imatinib; side effect
|
|
Indexed keywords
IMATINIB;
ADJUVANT CHEMOTHERAPY;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
CARDIOTOXICITY;
CARDIOVASCULAR DISEASE;
DRUG WITHDRAWAL;
DYSPNEA;
EUROPE;
FATIGUE;
GASTROINTESTINAL STROMAL TUMOR;
HEART LEFT VENTRICLE FAILURE;
HUMAN;
LIFE EXPECTANCY;
PATIENT COMPLIANCE;
PATIENT PREFERENCE;
PERIPHERAL EDEMA;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
REVIEW;
RISK BENEFIT ANALYSIS;
TREATMENT DURATION;
ANTINEOPLASTIC AGENTS;
CHEMOTHERAPY, ADJUVANT;
DRUG ADMINISTRATION SCHEDULE;
DRUG COSTS;
GASTROINTESTINAL NEOPLASMS;
GASTROINTESTINAL STROMAL TUMORS;
HUMANS;
MEDICATION ADHERENCE;
PIPERAZINES;
PYRIMIDINES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
TIME FACTORS;
|
|
EID: 84865632807
PISSN: 10781552
EISSN: 1477092X
Source Type: Journal
DOI: 10.1177/1078155212453606 Document Type: Review |
|
Times cited : (3)
|
|
References (5)
|
